Comparison · NCT04501666-988a0d96
Nemolizumab vs Placebo: Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nemolizumab vs Placebo: Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4. Trial comparisons, record NCT04501666-988a0d96. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04501666-988a0d96
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.411 | 0.343 | 0.482 | wilson | |
| Risk in group 2 | 0.0625 | 0.029 | 0.13 | wilson | |
| Risk difference, group 1 minus group 2 | 0.348 | 0.253 | 0.427 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 6.57 | 2.97 | 14.5 | log | |
| Odds ratio, group 1 over group 2 | 10.4 | 4.35 | 25.1 | log | |
| Number needed to treat, for one more participant with the outcome on Nemolizumab than on Placebo | 2.87 | 2.34 | 3.96 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nemolizumab | Participants weighing \<90 kg received two SC injections of 30 mg nemolizumab (60 mg loading dose) at baseline then one SC injection Q4W. Participants weighing \>=90 kg received two SC injections of 30 mg nemolizumab (60 mg total) at baseline (no loading dose) and two SC injections Q4W throughout the treatment period of 16 weeks.~Nemolizumab: Participants received either 30 mg or 60 mg dose of nemolizumab as SC injection. | 78 | 190 | OG000 |
| Group 2 | Placebo | Participants weighing \<90 kg received two SC injections of matching placebo at baseline, then one SC injection Q4W. Participants weighing \>=90 kg received two SC injections of matching placebo at baseline, then two SC injections Q4W throughout the treatment period of 16 weeks.~Placebo: Participants received matching placebo as SC injection. | 6 | 96 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With an Improvement of >= 4 From Baseline in Weekly Average PP NRS at Week 4
- Description
The Peak Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. For maximum itch intensity: the scores were provided on a scale of 0 to 10, with 0 being 'no itch' and 10 being 'worst itch imaginable'. Higher scores indicate worse outcome. Weekly values are calculated as average of 7 consecutive days data up to the target study day (excluding) and set to missing, if less than 4 days data are available. Analysis window extension was applied to baseline, as described in the SAP. If a participant received any rescue therapy, composite variable strategy is applied, the underlying data at/after receipt of rescue therapy is set as worst possible value, and the response is derived from underlying data value. Participants with missing results are considered as non-responders.
- Time frame
- Baseline, Week 4
- Population
- ITT population included all randomized participants.
Source ClinicalTrials.gov
Trial
- Title
- Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
- NCT number
- NCT04501666
- Phases
- PHASE3
- Conditions
- Prurigo Nodularis
- Interventions
- Nemolizumab 30 mg, Placebo
- Lead sponsor
- Galderma R&D
- Results first posted
- 2024-07-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04501666?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04501666-988a0d96